Von Willebrand factor: More than a regulator of hemostasis and thrombosis

Acta Haematologica

Volumn 128, Issue 3, 2012, Pages 158-169

  Luo, Gui Ping ^a   Ni, Bing ^a   Yang, Xia ^a   Wu, Yu Zhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

ADAMTS13; Angiogenesis; Tumors; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; CELL PROLIFERATION; HEMOSTASIS; LIVER DISEASE; METASTASIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ADHESION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BIOLOGICAL MARKERS; HEMOSTASIS; HUMANS; PLATELET ADHESIVENESS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84864808500     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000339426     Document Type: Review

References (90)

1. De Meyer SF, Deckmyn H, Vanhoorelbeke K: von Willebrand factor to the rescue. Blood 2009; 113: 5049-5057.
2. Petri B, Broermann A, Li H, Khandoga AG, Zarbock A, Krombach F: von Willebrand factor promotes leukocyte extravasation. Blood 2010; 116: 4712-4719.
3. Dasgupta S, Repesse Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamaté C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S: vWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-612.
4. Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, Orkin SH: Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 1401-1406.
5. Allen S, Abuzenadah AM, Hinks J, Blagg JL, Gursel T, Ingerslev J, Goodeve AC, Peake IR, Daly ME: A novel von Willebrand diseasecausing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood 2000; 96: 560-568.
6. Wagner DD, Marder VJ: Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 1984; 99: 2123-2130.
7. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K: Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-3184.
8. Wang JW, Valentijn KM, de Boer HC, Dirven RJ, van Zonneveld AJ, Koster AJ, Voorberg J, Reitsma PH, Eikenboom J: Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease. J Biol Chem 2011; 286: 24180-24188.
9. Zarei S, Frieden M, Rubi B, Villemin P, Gauthier BR, Maechler P, Vischer UM: Dopamine modulates von Willebrand factor secretion in endothelial cells via D2-D4 receptors. J Thromb Haemost 2006; 4: 1588-1595.
10. Lenting PJ, Pegon JN, Groot E, de Groot PG: Regulation of von Willebrand factor-platelet interactions. Thromb Haemost 2010; 104: 449-455.
11. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, de Groot PG, Denis CV: An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279: 12102-12109.
12. van Schooten CJ, Shahbazi S, Groot E, Oortwijn BD, Marijke Van den B, Ceclie VD, Lenting PJ: Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2005; 112: 1704-1712.
13. Crawley JT, Groot RD, Xiang Y, Luken BM, Lane DA: Unravelling the scissile bond: how ADAMTS13 recognises and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
14. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV, Moake JL, Lopez JA: Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002; 99: 3971-3977.
15. Furlan M, Robles R, Lämmle B: Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
16. Rens de G, David AL, Crawley JTB: The ADAMTS13 metalloprotease domain roles of subsites in enzyme activity and specificity. Blood 2010; 116: 3064-3072.
17. Zanardelli S, Chion AC, Groot E, Lenting PJ, Mckinnon TA, Laffan MA, Tseng M, Lane DA: A novel binding site for ADAMTS13 constitutively exposed on the surface of globular vWF. Blood 2009; 114: 2819-2828.
18. Luken BM, Winn LYN, Emsley J, Lane DA, Crawley JTB: The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood 2010; 115: 4910-4913.
19. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL: Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-1674.
20. Tao Z, Wang Y, Choi H, Bernardo A, Nishio K, Sadler JE, López JA, Dong JF: Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood 2005; 106: 141-143.
21. Wang A, Liu F, Dong N, Ma Z, Zhang J, Su J, Zhao Y, Ruan C: Thrombospondin-1 and ADAMTS13 competitively bind to vWF A2 and A3 domains in vitro. Thromb Res 2010; 126: 260-265.
22. Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ: Role of thrombospondin-1 in control of von Willebrand Factor multimer size in mice. J Biol Chem 2004; 279: 21439-21448.
23. Bonnefoy A, Daenens K, Feys HB, Vos RD, Vandervoort P, Vermylen J, Lawler J, Hoylaerts MF: Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial vWF from cleavage by ADAMTS13. Blood 2006; 107: 955-964.
24. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE: Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
25. Shankaran H, Alexandridis P, Neelamegham S: Aspects of hydrodynamic shear regulating shear-induced platelet activation and selfassociation of von Willebrand factor in suspension. Blood 2003; 101: 2637-2645.
26. Dong JF: Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-1716.
27. Zhang XH, Halvorsen K, Zhang CZ, Wong WP, Springer TA: Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009; 324: 1330-1334.
28. Andrews RK, Berndt MC: Platelet physiology and thrombosis. Thromb Res 2004; 114: 447-453.
29. Hoffmeister KM, Felbinger TW, Falet H, Denis CV, Bergmeier W, Mayadas TN, von Andrian UH, Wagner DD, Stossel TP, Hartwig JH: The clearance mechanism of chilled blood platelets. Cell 2003; 112: 87-97.
30. Cheng H, Yan R, Li S, Yuan Y, Liu J, Ruan C, Dai K: Shear-induced interaction of platelets with von Willebrand factor results in glycoprotein Ib-shedding. Am J Physiol Heart Circ Physiol 2009; 297: 2128-2135.
31. Mody NA, Lomakin O, Doggett TA, Diacovo TG, King MR: Mechanics of transient platelet adhesion to von Willebrand factor under flow. Biophys J 2005; 88: 1432-1443.
32. Huang J, Roth R, Heuser JE, Sadler JE: Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood 2009; 113: 1589-1597.
33. Fuchs B, Budde U, Schulz A, Kessler CM, Fisseau C, Kannicht C: Flow-based measurements of von Willebrand factor (vWF) function: binding to collagen and platelet adhesion under physiological shear rate. Thromb Res 2010; 125: 239-245.
34. Bonnefoy A, Romijn RA, Vandervoort PAH, Van Rompaey I, Vermylen J, Hoylaerts MF: von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost 2006; 4: 2151-2161.
35. Ridddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, Sutherland M, Laffan MA, Mckinnon TA: Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009; 114: 3489-3496.
36. Romijn RA, Westein E, Bouma B, Schiphorst ME, Sixma JJ, Lenting PJ, Huizinga EG: Mapping the collagen-binding site in the von Willebrand Factor A3-domain. J Biol Chem 2003; 278: 15035-15039.
37. Bovenschen N, Mertens K, Hu L, Havekes L, van Vlijmen B: LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005; 106: 906-912.
38. Fressinaud E, Meyer D: International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993; 70: 546.
39. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR: Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94: 1070-1076.
40. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TAJ, Sutton PE, Payne EM, Haskard DO: Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117: 1071-1080.
41. Tigges U, Hyer EG, Scharf J, Stallcup WB: FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development 2008; 135: 523-532.
42. Qin F, Impeduglia T, Schaffer P, Dardik H: Over-expression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies. J Vasc Surg 2003; 37: 433-439.
43. Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ, Denis CV: Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 2006; 4: 519-526.
44. Terraube V, Marx I, Denis CV: Role of von Willebrand factor in tumor metastasis. Thromb Res 2007; 120(suppl 2):S64-S70.
45. Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ, Denis CV: Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 2006; 4: 519-526.
46. Brinkmann V, Reichard U, Goosmann C, Fauler B, Weiss DS, Weinrauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
47. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD: Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
48. Nurden P, Gobbi G, Nurden A, Enouf J, Youlyouz-Marfak I, Carubbi C, La Marca S, Punzo M, Baronciani L, De Marco L, Vitale M, Federici AB: Abnormal vWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010; 115: 2649-2656.
49. Trossaert M, Ternisien C, Lefrancois A, Llopis L, Goudemand J, Sigaud M, Fouassier M, Caron C: Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease. Clin Appl Thromb Hemost 2011; 17:E25-E29.
50. Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A: Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Acta Haematol 2009; 121: 167-176.
51. Moore JC, Hayward CP, Warkentin TE, Kelton JG: Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-1846.
52. Moake J, Rudy C, Troll J, Weinstein M, Colannino N, Azocar J, Seder R, Hong S, Deykin D: Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
53. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammie B: Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
54. Moake JL: Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
55. Dong JF, Moake JL, Nolasco L: ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
56. Levy VG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemienia DR, Stark KR, Gruppok R, Sarode R, Shurin SB, Chandrasekaran V: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
57. Caprioli J, Castelletti F, Bucchioni S: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndromethe C-257T the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385-3395.
58. Shetty S, Kasatkar P, Ghosh K: Pathophysiology of acquired von Willebrand disease: a concise review. Eur J Haematol 2011; 87: 99-106.
59. Leimkuhler K, Bach F, Kuhlmann S, Feidicker B, Heim MU, Susemihl C, Schmidt B, Mertzlufft F: Acquired von Willebrand's disease type 2A following arteriovenous fistula for haemodialysis? (in German) Hämostaseologie 2011; 31: 118-122.
60. Michiels JJ, Schroyens W, Berneman Z, van der Planken M: Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost 2001; 7: 113-115.
61. Drouin J, Lillicrap DP, Izaguirre CA, Sutherland M, Windsor S, Benford K, Hoogendorn H, Giles AR: Absence of a bleeding tendency in severe acquired von Willebrand's disease: the role of platelet von Willebrand factor in maintaining normal hemostasis. Am J Clin Pathol 1989; 92: 471-478.
62. Karger R, Weippert-Kretschmer M, Budde U, Kretschmer V: Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome. Blood Coagul Fibrinolysis 2011; 22: 144-147.
63. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I: Endothelial cell markers and the risk of coronary heart disease: the prospective epidemiological study of myocardial infarction (PRIME) study. Circulation 2004; 109: 1343-1348.
64. Blann AD, McCollum CN, Lip GY: Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagul Fibrinolysis 2002; 13: 513-518.
65. Yavuz BB, Dede DS, Yavuz B, Cankurtaran M, Halil M, Ulger Z, Cankurtaran ES, Aytemir K, Kabakci G, Haznedaroglu IC, Ariogul S: Potential biomakers for vascular damage in Alzheimer's disease: thrombomodulin and von Willebrand factor. J Nutr Health Aging 2010; 14: 439-441.
66. Bugnicourt JM, Roussel B, Tramier B, Lamy C, Godefroy O: Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study. J Neurol Neurosurg Phychiatry 2007; 78: 699-701.
67. Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, Elvin K, Simard JF, Hansson LO, Lundberg IE, Larsson A, Svenungsson E: Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 2009; 11: 186-196.
68. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW: High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672-2677.
69. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, Bosch J, Garcia-Pagan JC: Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011; 60: 1133-1138.
70. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY: Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57: 2496-2504.
71. Khaleghi M, Singletary L, Kondragunta V, Bailey KR, Turner ST, Mosley TH Jr, Kullo IJ: Haemostatic markers are associated with measures of vascular disease in adults with hypertension. J Hum Hypertens 2009; 23: 530-537.
72. Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, López JA: The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood 2011; 117: 3680-3683.
73. Cugno M, Castelli R, Mari D, Mozzi E, Zappa MA, Boscolo-Anzoletti M, Roviaro G, Mannucci PM: Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding. Intern Emerg Med 2012; 7: 237-242.
74. Francisco C, Juan AV, Antonio GH, Francisco RE: Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thromb Res 2010; 126: 46-50.
75. Conroy AL, Phiri H, Hawkes M, Glover S, Mallewa M, Seydel KB, Taylor TE, Molyneux ME, Kain KC: Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective casecontrol study. PLoS ONE 2010; 5:e15291.
76. Spiel AO, Gilbert JC, Jilma B: von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117: 1449-1459.
77. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW: Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
78. Zetterberg E, Lundberg LG, Palmblad J: Characterization of blood vessels in bone marrow from patients with chronic myeloid leukemia and polycythemia vera. Scand J Clin Lab Invest 2004; 64: 641-647.
79. Hatzipantelis ES, Athanassiou-Metaxa M, Gombakis N, Tzimouli V, Taparkou A, Sidi-Fragandrea V, Garipidou V, Papageorgiou T, Kleta D, Koliouskas DE, Athanasiadou-Piperopoulou F: Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia. Acta Haematol 2011; 125: 130-135.
80. Liu G, Ren YM: Effect of von Willebrand factor on the biological characteristics of colorectal cancer cells. Zhonghua Wei Chang Wai Ke Za Zhi 2010; 13: 616-619.
81. Kim SM, Myoung H, Choung PH, Kim MJ, Lee SK, Lee JH: Metastatic leiomyosarcoma in the oral cavity: case report with protein expression profiles. J Craniomaxillofac Surg 2009; 37: 454-460.
82. Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE: Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 2006; 6: 16.
83. Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A: Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 2005; 48: 577-583.
84. Schellerer VS, Mueller-Bergh L, Merkel S, Zimmermann R, Weiss D, Schlabrakowski A, Naschberger E, Sturzl M, Hohenberger W, Croner RS: The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res 2011; 3: 445-453.
85. Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, Rank A, Gohring P, Thaler CJ, Friese K, Bauerfeind I: Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res 2008; 28: 1107-1112.
86. Martini F, Ferroni P, Guadagni F, Basili S, Spila A, D'Alessandro R, Mineo D, Laudisi A, Portarena I, Mariotti S, Ambrogi V, Mineo TC, Roselli M: Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients. Anticancer Res 2005; 25: 403-407.
87. Caine GJ, Lip GY, Blann AD: Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004; 36: 273-277.
88. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J: Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-1777.
89. Sinha S, Cao Y, Dutta S, Wang E, Mukhopadhyay D: VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma. J Cell Mol Med 2010; 14: 647-658.
90. Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, Klimpfinger M, Denk H, Zatloukal K: Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 2004; 445: 160-167.